MD Biosciences performs efficacy studies for proof-of-concept as well as assays for early screening and profiling of drug candidates for use in airway inflammation therapies. If there is a model or assay that you don't see listed, please contact a representative to discuss a custom assay design.
OVA Induced Allergic Asthma
Ovalbumin-induced allergic asthma is a widely used model to reproduce the airway eosinophilia, pulmonary inflammation and elevated IgE levels found during asthma. Studies can be run with or without airway hyper-responsiveness (AHR) measurements.
Whitepaper: OVA-induced Asthma. The importance of suitable efficacy models to aid in the discovery of novel treatments.
LPS Lung Inflammation Model
An acute model of pulmonary inflammation induced by the intranasal administration of LPS. This is a rapid model where leukocytes (mainly neutrophils) are recruited to the lung within 4 hours of LPS treatment. It is possible to measure and characterize the cellular profile of recruited leukocytes to the lung airways as well as the levels of pro-inflammatory cytokines.
Passive Cutaneous Anaphylaxis (PCA)
The rapid passive cutaneous anaphylaxis model is a useful initial model for test items believed to work upon mast cells. In 24 hours, it can reveal whether the therapy is able to prevent the degranulation of mast cells - a major factor in the induction of an asthmatic response.